Single-dose pharmacokinetics of the DNA-binding bioreductive agent NLCQ-1 (NSC 709257) in CD2F1 mice

Cancer Chemotherapy and Pharmacology

Volumn 51, Issue 6, 2003, Pages 483-487

  Reid, Joel M ^a   Squillace, David P ^a   Ames, Matthew M ^a  

^a MAYO CLINIC   (United States)

Author keywords

Bioreductive compounds; DNA; HPLC; Mice; Pharmacokinetics

Indexed keywords

4 [3 (2 NITROIMIDAZOLYL)PROPYLAMINO] 7 CHLOROQUINOLINE; ANTINEOPLASTIC AGENT; NSC 13248; NSC 709257; OROSOMUCOID; SERUM ALBUMIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CALIBRATION; COMPARTMENT MODEL; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DNA BINDING; DRUG EXCRETION; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG STABILITY; EXPERIMENTAL MOUSE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE;

EID: 0037713601     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-003-0570-7     Document Type: Article

References (15)

1. Bradner WT (2001) Mitomycin C: a clinical update. Cancer Treat Rev 27:35
2. Fuse E, Tanii H, Kurata N, Kobayashi H, Shimada Y, Tamura T, Sasaki Y, Tanigawara Y, Lush RD, Headlee D, Figg WD, Arbuck SG, Senderowicz AM, Sausville EA, Akinaga S, Kuwabara T, Kobayashi S (1998) Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alphal-acid glycoprotein. Cancer Res 58:3248
3. Gibaldi M, Perrier D (1982) Pharmacokinetics, 2nd edn. Marcel Dekker, New York, p 409
4. Höckel M, Vaupel P (2001) Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 93:266
5. Lee DJ, Trotti A, Spencer S, Rostock R, Fisher C, von Roemeling R, Harvey E, Groves E (1998) Concurrent tirapazamine and radiotherapy for advanced head and neck carcinomas: a phase II study. Int J Radiat Oncol Biol Phys 42:811
6. Papadopoulou MV, Ji M, Bloomer WD (1996) THNLA-1 as radio/chemosensitizer of EMT-6 tumours in mice. Br J Cancer 74:S267
7. Papadopoulou MV, Ji M, Rao MK, Bloomer WD (1996) 9-[3-(2-Nitro-1-imidazolyl)propylamino]-cyclopenteno[b]quinoline hydrochloride (NLCPQ-1). A novel DNA-affinic bioreductive agent as cytotoxin and radiosensitizer. Oncol Res 8:425
8. Papadopoulou MV, Ji M, Bloomer WD (1998) NLCQ-1, a novel hypoxic cytotoxin: potentiation of melphalan, cisDDP and cyclophosphamide in vivo. Int J Radiat Oncol Biol Phys 42:775
9. Papadopoulou MV, Ji M, Rao MK, Bloomer WD (2000) 4-[3-(2-Nitro-1-imidazolyl)propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive agent as radiosensitizer in vitro and in vivo: comparison with tirapazamine. Oncol Res 12:325
10. Papadopoulou MV, Ji M, Rao MK, Bloomer WD (2000) 4-[3-2-Nitro-1-imidazolyl)propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive compound as a hypoxia-selective cytotoxin. Oncol Res 12:185
11. Papadopoulou MV, Ji M, Bloomer WD (2001) Schedule-dependent potentiation of chemotherapeutic drugs by the bioreductive compounds NLCQ-1 and tirapazamine against EMT6 tumors in mice. Cancer Chemother Pharmacol 48:160
12. Papadopoulou MV, Ji M, Ji X, Bloomer WD (2002) Therapeutic advantage from combining 5-fluorouracil with the hypoxia-selective cytotoxin NLCQ-1 in vivo; comparison with tirapazamine. Cancer Chemother Pharmacol 50:291
13. Rauth AM, Melo T, Misra V (1998) Bioreductive therapies: an overview of drugs and their mechanisms of action. Int J Radiat Oncol Biol Phys 42:755
14. Senan S, Rampling R, Graham MA, Wilson P, Robin H Jr, Eckardt N, Lawson N, McDonald A, von Roemeling R, Workman P, Kaye SB (1997) Phase I and pharmacokinetic study of tirapazamine (SR 4233) administered every three weeks. Clin Cancer Res 3:31
15. Teicher BA, Holden SA, Al-Achi A, Herman TS (1990) Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in the FSaIIC murine fibrosarcoma. Cancer Res 50:3339